ARGENX SEARGX

時価総額

PER

免疫疾患向けバイオ医薬品の有力企業。FcRn阻害薬やVYVGARTなどの治療薬を展開。2023年7月に12億ドルの公募増資、2023年6月にHYTRULO承認、2030年に第3相5剤・5万人治療目標。米国・欧州・日本中心に展開。

	2018年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Operating profit/(loss)	-82	-349	-720	-425	-22
Amortization of intangible assets	-	1	100	106	10
Adjustments for depreciation expense	-	5	5	6	7
Adjustments for provisions	-	0	0	1	0
Adjustments for share-based payments	-	179	157	233	235
Adjustments for fair value losses (gains)	-	-11	-4	-	-4
Loss from investment in a joint venture	-	-	1	4	-8
Other non-cash (benefit)/expenses	-	-	-	2	-0
Adjustments for non-cash items	-	-249	-462	-74	235
(Increase)/decrease in trade and other receivables	-	-32	-222	-186	-423
(Increase)/decrease in inventories	-	-84	-119	-83	-96
(Increase)/decrease in other current assets	-1	-31	-18	-59	-56
Increase/(decrease) in trade and other payables	-	135	0	96	246
(Increase)/decrease in other non‑current assets	-	-14	-16	-29	-20
(Increase)/decrease in non-current prepaid expense	-	-	-	-47	24
Net cash flows used in operating activities, before interest and taxes	-53	-590	-838	-383	-90
Interest paid	-	1	1	0	0
Income taxes received/(paid)	-	16	24	38	-8
Net cash flows used in operating activities	-	-607	-863	-420	-83
Purchase of intangible assets	-	118	103	43	67
Purchase of property, plant and equipment	-	4	1	1	2
Purchase of current financial assets	-	-	1,694	1,272	2,184
Sale of current financial assets	-	-	1,326	1,544	1,430
Interest received	-	3	13	93	112
Investment in a joint venture	-	-	2	13	7
Net cash flows from/(used in) investing activities	-	-347	-461	308	-718
Principal elements of lease payments	-	4	4	4	8
Proceeds from issue of ordinary shares	-	1,091	761	1,197	-
Issue costs paid	-	1	1	1	-
Exchange Gain From Currency Conversion On Proceeds From Issue Of New Shares	-	1	0	-2	-
Payment of employee withholding taxes relating to restricted stock unit awards	-	-	6	12	22
Proceeds from exercise of options	-	33	93	158	309
Net cash flows from financing activities	-	1,121	844	1,337	280
Increase/(decrease) in cash and cash equivalents	-	167	-480	1,225	-521
Exchange gains/(losses) on cash and cash equivalents	-	-50	-54	23	-28